Aktis OncologyAKTS -5.49%9 Market Cap is $1,623.50 Mil as of Jun. 28, 2026. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 3 warning signs investors should review. Among 1,429 Biotechnology companies, Aktis Oncology ranks better than 85.37% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Aktis Oncology's share price for the quarter that ended in Mar. 2026 was $17.89. Aktis Oncology's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 55.28 Mil. Therefore, Aktis Oncology's market cap for the quarter that ended in Mar. 2026 was $988.89 Mil.
Aktis Oncology's quarterly market cap
stayed the same
from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) but then
increased
from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($988.89 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aktis Oncology's Enterprise Value for Today is $1,096.59 Mil.
Aktis Oncology (NAS:AKTS) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Aktis Oncology Market Cap Related Terms
Aktis Oncology Market Cap Historical Data
* Premium members only.
The historical data trend for Aktis Oncology's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aktis Oncology's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aktis Oncology Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aktis Oncology's Market Cap distribution charts can be found below:
* The bar in red indicates where Aktis Oncology's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Aktis Oncology's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aktis Oncology (AKTS) has a Market Cap of $1,623.50 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aktis Oncology and its competitors. According to the industry distribution chart, Aktis Oncology ranks #209 out of 1429 companies in the Biotechnology industry, placing it in the top 14.6%.
Is Aktis Oncology's Market Cap too high?
Aktis Oncology's current Market Cap is $1,623.50 Mil. The Biotechnology industry median Market Cap is 112.70. Aktis Oncology's value of $1,623.50 Mil is 1340.6% above this industry median. Based on the distribution chart, Aktis Oncology ranks #209 out of 1429 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Market Cap compare to OLMA and EYPT?
According to the Biotechnology industry distribution chart, Aktis Oncology ranks #209 out of 1429 companies for Market Cap. This places Aktis Oncology in the top 15% of its industry — outperforming the majority of peers. The industry median Market Cap is 112.70. Aktis Oncology's value of $1,623.50 Mil is 1340.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.70, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aktis Oncology's current Market Cap of $1,623.50 Mil is 1340.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Aktis Oncology and its competitors. For the Biotechnology industry, the median Market Cap is 112.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aktis Oncology's current Market Cap is $1,623.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Market Cap of $1,623.50 Mil. The current Market Cap is $1,623.50 Mil and 1340.6% above the Biotechnology industry median of 112.70. Aktis Oncology's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Market Cap is $1,623.50 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score
Get the complete analysis for AKTS
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKTS has been successfully added to your 